BLA 125387 · Regeneron Pharmaceuticals
Eylea
Aflibercept · Injection · Vascular Endothelial Growth Factor Inhibitor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Nov 18, 2011
Approved uses
8
Original approval plus efficacy supplements
Registered trials
474
135 Phase 3, 39 recruiting
FAERS reports
30,249
24,786 serious, 8,878 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 7, 2026.
EYLEA is indicated for the treatment of: EYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Retinopathy of Prematurity (ROP) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Retinopathy of Prematurity (ROP)
Mechanism: Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which is also present on the surface of leucocytes. Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability. Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF, and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 8, 2023 Supplement 75 · Efficacy · priority review OrphanLetterLabel
- May 13, 2019 Supplement 61 · Efficacy LabelLetterReview
- Aug 16, 2018 Supplement 56 · Efficacy LabelLetter
- Mar 25, 2015 Supplement 48 · Efficacy · priority review Breakthrough therapyReviewLetterLabel
- Oct 6, 2014 Supplement 43 · Efficacy LabelLetter
- Jul 29, 2014 Supplement 37 · Efficacy Letter
- Sep 21, 2012 Supplement 4 · Efficacy LabelLetter
- Nov 18, 2011 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- EYLEA · AFLIBERCEPT 40MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Aflibercept" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 1Pivotal-lookingCompleted
Alcon ResearchIndustry
NCT02307682 · 1,775 participants · Start Dec 8, 2014 · Primary completion Apr 22, 2017
Drug: Brolucizumab ophthalmic solution; Aflibercept ophthalmic solution · For: Neovascular Age-Related Macular Degeneration; Choroidal Neovascularization
Sites: Fort Worth, Texas
- Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00637377 · 1,240 participants · Start Apr 2008 · Primary completion Sep 2010
Drug: Ranibizumab; Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) and 2 more · For: Macular Degeneration
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Rosario, Argentina · 189 sites in all
- Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based RegimenPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00561470 · 1,226 participants · Start Nov 2007 · Primary completion Feb 2011
Drug: Placebo; Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) and 2 more · For: Colorectal Neoplasms; Neoplasm Metastasis
Sites: Birmingham, Alabama; Muscle Shoals, Alabama; Hot Springs, Arizona · 221 sites in all
- Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate CancerPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00519285 · 1,224 participants · Start Aug 2007 · Primary completion Apr 2012
Drug: Aflibercept; Placebo (for aflibercept) and 2 more · For: Prostatic Neoplasms; Neoplasm Metastasis
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Macquarie Park, Australia · 31 sites in all
- Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT00509795 · 1,217 participants · Start Aug 2007 · Primary completion Sep 2010
Drug: ranibizumab; aflibercept injection (VEGF Trap-Eye, BAY86-5321) and 2 more · For: Macular Degeneration
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 188 sites in all
- Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)Pivotal-lookingTerminated
Chengdu Kanghong Biotech Co., Ltd.Industry
NCT03630952 · 1,157 participants · Start Dec 21, 2018 · Primary completion Sep 10, 2020
Drug: 0.5 mg Conbercept Intravitreal Injection; 1.0 mg Conbercept Intravitreal Injection and 1 more · For: Neovascular Age-related Macular Degeneration
Sites: Phoenix, Arizona; Springdale, Arkansas; Arcadia, California · 154 sites in all
- Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)Pivotal-lookingTerminated
Chengdu Kanghong Biotech Co., Ltd.Industry
NCT03577899 · 1,157 participants · Start Sep 25, 2018 · Primary completion Sep 25, 2020
Drug: 0.5 mg Conbercept Intravitreal Injection; 1.0 mg Conbercept Intravitreal Injection and 1 more · For: Neovascular Age-related Macular Degeneration
Sites: Phoenix, Arizona; Tucson, Arizona; Beverly Hills, California · 179 sites in all
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)Pivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06491914 · 1,126 participants · Start Jul 24, 2024 · Primary completion Aug 26, 2025
Drug: Aflibercept 8 mg · For: Neovascular Age-Related Macular Degeneration; Diabetic Macular Edema
Sites: Arcadia, California; Bakersfield, California; Beverly Hills, California · 54 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death7,876
- visual impairment2,037
- off label use1,631
- blindness1,437
- endophthalmitis1,341
- visual acuity reduced1,236
- drug ineffective1,188
- eye pain1,162
- vision blurred1,149
- product dose omission issue1,106
- blindness unilateral1,048
- blindness transient977
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 5 |
| 2008 | 2 |
| 2009 | 11 |
| 2010 | 45 |
| 2011 | 27 |
| 2012 | 172 |
| 2013 | 575 |
| 2014 | 852 |
| 2015 | 1,499 |
| 2016 | 2,240 |
| 2017 | 2,841 |
| 2018 | 4,387 |
| 2019 | 4,417 |
| 2020 | 3,536 |
| 2021 | 1,917 |
| 2022 | 1,690 |
| 2023 | 1,473 |
| 2024 | 2,271 |
| 2025 | 1,098 |
| 2026 | 1,191 |
Recalls
2 FDA enforcement reports for this application.
May 15, 2024 · Class II · Terminated
Lack of Assurance of Sterility: Complaints of syringe breakage
Apr 23, 2024 · Class II · Terminated
Lack of Assurance of Sterility: Complaints of syringe breakage
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Eylea (Aflibercept)
2024 spending
$71.1M
Beneficiaries
7,368
29,232 claims
Per beneficiary
$9,656
$37,751.23 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $25,587,701 |
| 2021 | $31,166,271 |
| 2022 | $68,312,404 |
| 2023 | $73,869,613 |
| 2024 | $71,144,895 |
Part B: Eylea (Aflibercept) · HCPCS J0178
2024 spending
$2.37B
Beneficiaries
293,280
1,233,027 claims
Per beneficiary
$8,065
2024 ASP limit $840.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,013,346,116 |
| 2021 | $3,415,890,772 |
| 2022 | $3,541,909,704 |
| 2023 | $3,148,337,301 |
| 2024 | $2,365,369,089 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, et al. · Ophthalmology 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Heier JS, Brown DM, Chong V, et al. · Ophthalmology 2012 · Clinical Trial, Phase III, Comparative Study
- Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Lanzetta P, Korobelnik JF, Heier JS, et al. · Lancet 2024 · Clinical Trial, Phase III, Equivalence Trial
- Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, et al. · Ophthalmology 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, et al. · Lancet 2022 · Clinical Trial, Phase III, Equivalence Trial
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU, Koh A, Ogura Y, et al. · Ophthalmology 2020 · Clinical Trial, Phase III, Comparative Study
Sponsor: Regeneron
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.